Alligator Bioscience Presents New Data on Mitazalimab and ATOR-4066 at SITC 40th Anniversary Annual Meeting

November 5, 2025 5:20 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced the publication of two abstracts accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, to be held 5-9 November 2025 in National Harbor, MD, USA.The mitazalimab abstract presents new data from the OPTIMIZE-1 trial in metastatic...

Read more

Vicore to Present at Upcoming Investor Conferences

November 5, 2025 2:50 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following conferences:Guggenheim's Second Annual Healthcare Innovation ConferenceLocation: Boston, USAFormat: Fireside chat and 1×1 meetingsPresentation Date and Time: Monday, November 10 at 9:00 AM ETWebcast: RegistrationParticipants: Ahmed Mousa, CEO, and Megan Richards,...

Read more

Interim Report July - September 2025

November 5, 2025 2:15 AM

Vicore Pharma Holding (STO:VICO) - Stockholm, November 5, 2025 - Vicore Pharma Holding AB (STO:VICO) unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the third quarter 2025."ASPIRE is on track to complete enrollment in the first half of 2026, with continued enthusiasm fueled by new data supporting buloxibutid's disease-modifying signal in the Phase 2a AIR...

Read more

Taran Therapeutics Reports Publication of ASH Abstracts for Clinical Treatment with Lenzilumab in Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

November 4, 2025 9:10 AM

Taran Therapeutics ("Taran") a privately held company focused on hematology/oncology, announced American Society of Hematology ("ASH") accepted abstracts for lenzilumab ("LENZ") at the 67th. ASH medical conference to be held December 4-7, 2025, in Orlando, FL.Abstract number abs25-9821, titled ‘Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement',...

Read more

NAYA Therapeutics to Present at the Network for Optimized Astatine-Labeled Radiopharmaceuticals (NOAR) Europe Annual Meeting

November 4, 2025 4:00 AM

NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of Astatine-211 (²¹¹At) targeted alpha therapies and natural killer (NK) cell engaging bifunctional antibodies, today announced that it will be presenting its strategic development plans to establish a global decentralized supply chain and clinical development initiation for its ²¹¹At targeted...

Read more

Faron Announces Two Bexmarilimab Abstracts Accepted At Ash 2025, Including An Oral Presentation On Treatment Efficacy

November 4, 2025 2:15 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel treatments for medical conditions with significant unmet needs, today announced that two abstracts featuring data from the Phase 1/2 BEXMAB study have been accepted for presentation at the American Society of Hematology (ASH) 2025 Annual Meeting.Highlighting the growing body of evidence for bexmarilimab, an abstract detailing...

Read more

FluoGuide A/S Issue Warrants to Board Members, Executive Management and Employees

November 3, 2025 4:15 PM

FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") announces that it has issued 199,000 warrants to members of the board directors, members of the executive management and employees, based on the approved incentive program from 9 February 2021.Today, the Board of Directors of FluoGuide has exercised its authorization to issue new warrants by issuing 199,000 warrants. The warrants are issued as part of the remuneration of the individuals....

Read more

FluoGuide A/S Completes Directed Share Issue of SEK 104 Million

November 3, 2025 3:50 PM

FluoGuide A/S (STO:FLUO) - FluoGuide A/S ("FluoGuide" or the "Company") has, in accordance with the Company's press release earlier today, resolved on a directed share issue of 2,729,164 shares at a subscription price of SEK 38 per share, raising SEK 104 million in gross proceeds through an accelerated book building process (the "Directed Share Issue"). Several Nordic institutional investors, including large existing shareholders, participated...

Read more

FluoGuide A/S Intends to Carry Out a Directed Share Issue of Approximately SEK 100 Million

November 3, 2025 12:00 PM

FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") announces its intention to carry out a directed share issue of approximately SEK 100 million to institutional and other qualified investors through an accelerated bookbuilding process (the "Directed Share Issue"). The subscription price in the Directed Share Issue will be determined through an accelerated bookbuilding procedure (the "Bookbuilding") which will commence immediately following...

Read more

BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025

November 3, 2025 9:17 AM

BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will present new data from the safety run-in portion of its ongoing trial evaluating BI-1206 in combination with rituximab and Calquence ® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL) in...

Read more

BioInvent to Present Updated Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025

November 3, 2025 9:15 AM

BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will present updated data from the ongoing Phase 2a monotherapy of BI-1808, a first-in-class anti-TNFR2 antibody, in cutaneous T-cell lymphoma (CTCL) in a poster at the upcoming 2025 American Society of...

Read more

Nomination Committee Appointed in Respect of AGM 2026 in Alligator Bioscience AB

November 3, 2025 9:15 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that the Nomination Committee in preparation for the Annual General Meeting (AGM) on May 6, 2026, has been appointed.Pursuant to the instruction for the Nomination Committee adopted by the AGM in 2019, the Nomination Committee for the Alligator Bioscience AGM 2026 shall consist of four...

Read more

Prolocor Announces Publication in Journal of Invasive Cardiology. Prolocor pFCG Test is a Powerful Prognostic Marker of Ischemic Risk Early After Myocardial Infarction (MI).

November 3, 2025 9:00 AM

Prolocor, Inc., a healthcare startup developing the innovative diagnostic Prolocor pFCGTM test that identifies patients at higher and lower risk of thrombotic events (heart attack, stroke, and death), announced the publication entitled Prognostic Implications Over Time of Platelet FcɣRIIa Expression in Patients With Myocardial Infarction: A Secondary Analysis in the Journal of Invasive Cardiology.In an 800-patient multicenter study, patients...

Read more

Biohope Announces Collaboration to Advance Immunobiogram for Renal Transplant

November 3, 2025 9:00 AM

Biohope, a Spanish company specialized in personalized medicine solutions for transplant and autoimmune patients, has signed a know-how agreement with Mayo Clinic, a global leader in medical research and patient care, to advance the development and commercialization of the Immunobiogram, an in vitro diagnostic (IVD) device developed by Biohope and patented in the U.S. and other territories.The agreement grants Biohope access to Mayo Clinic's...

Read more

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

November 3, 2025 8:52 AM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced an expansion of its AI-powered in-Silico drug discovery platform. The company is now integrating more methodologies, including retrosynthetic analysis, molecular docking, toxicology and genotoxic assessments, and predictive bioactivity...

Read more

Vicore Announces The Nomination Committee For The 2026 Annual General Meeting

November 3, 2025 4:20 AM

Vicore Pharma Holding (STO:VICO) - Stockholm, November 3, 2025 - Vicore Pharma Holding AB (publ)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), has appointed the Nomination Committee for the 2026 Annual General Meeting (AGM). The three largest shareholders as of August 31, 2025, have each appointed a member to the Nomination Committee.The Nomination Committee consists of Staffan...

Read more

Faron Hits Key Milestone With Bexmab Phase 2 Completion, Advances To Registrational Trial With Fda Alignment

November 3, 2025 3:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Having achieved all primary endpoints and secured FDA alignment, Faron formally concludes enrolment of the BEXMAB Phase 2 trial as Company's focus shifts to a registrational trialTURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM:FARN, First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through immunotherapies, today announces the official completion of patient...

Read more

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

October 31, 2025 8:05 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today reported financial results for the third quarter 2025.Summary of Financial Results for the Third Quarter 2025The Company ended the quarter with $31.0 million in cash and investments. With the VenoValve commercializations costs and enVVe IDE expenses currently on hold pending...

Read more

CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference

October 30, 2025 4:10 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that CEO, Michael Heltzen, will be on the 'AI's Billion-dollar Bet on Life Sciences: From Drug Discovery to Patient Impact' panel at Beryl Elites' 7th Annual Investment Conference on November 4, 2025, in New York City.eXoZymes has developed a next...

Read more

Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds

October 30, 2025 9:32 AM

In the face of growing global concern over the potential use of chemical weapons such as the nerve agent Sarin, Lunai Bioworks Inc. (NASDAQ:LNAI) today announced promising early results from its AI-based platform designed to identify compounds that interact with acetylcholinesterase (AChE), the same molecular target affected by nerve agents."This research brings us closer to a future where proactive, AI-powered screening can detect and evaluate...

Read more